drugset / Trial / NCT07399444
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）
Phase 0
Not yet recruiting
38 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.
Timeline
- Start
- 2026-01-10
- Primary completion
- 2028-07-10
- Completion
- 2030-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVIVO-TaVec400 | Cell therapy | — | — |